[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@DaisukeKotani Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1968805680925786112.png) @DaisukeKotani Daisuke Kotani, MD, Ph.D 小谷 大輔

Daisuke Kotani, MD, Ph.D 小谷 大輔 posts on X about matterhorn, 1l the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1968805680925786112/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1968805680925786112/c:line/m:interactions.svg)

- X Week XXXXXX +4,489%

### Mentions: X [#](/creator/twitter::1968805680925786112/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1968805680925786112/c:line/m:posts_active.svg)

- X Week XX +450%

### Followers: XXX [#](/creator/twitter::1968805680925786112/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1968805680925786112/c:line/m:followers.svg)

- X Week XXX +455%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1968805680925786112/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1968805680925786112/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1968805680925786112/influence)
---

**Social category influence**
[travel destinations](/list/travel-destinations) 

**Social topic influence**
[matterhorn](/topic/matterhorn), [1l](/topic/1l)
### Top Social Posts [#](/creator/twitter::1968805680925786112/posts)
---
Top posts by engagements in the last XX hours

"LBA29: CheckMate 8HW Nivo+Ipi vs Nivo vs SOC for MSI-H/dMMR mCRC ✅1L PFS: NR vs XXXX mo HR XXXX p=0.0413 (prespecified threshold p0.0383) ✅TRAEs leading to treatment discontinuation: XX% vs X% (Grade 3-4 XX% vs 4%) 👉Although PFS difference between 1L Nivo + Ipi and Nivo was not statistically significant there appears to be a clear PFS benefit from 1L Nivo + Ipi to me. However caution is required regarding the increased incidence of irAEs. #ESMO25 @OncoAlert"  
[X Link](https://x.com/DaisukeKotani/status/1980399752245309856) [@DaisukeKotani](/creator/x/DaisukeKotani) 2025-10-20T22:24Z XXX followers, 2513 engagements


"DESTINY-CRC02: T-DXd XXX mg/kg vs XXX mg/kg for HER2+ mCRC ✅cORR XXXX% vs XXXX% ✅DOR XXX vs XXX mo ✅ILD XXX% vs XXXX% 👉T-DXd XXX mg/kg recommended for better risk-benefit balance #ESMO25 @myESMO @OncoAlert"  
[X Link](https://x.com/DaisukeKotani/status/1980033691364872274) [@DaisukeKotani](/creator/x/DaisukeKotani) 2025-10-19T22:09Z XXX followers, 2666 engagements


"LBA9: DYNAMIC-III ctDNA-guided adjuvant de-escalation strategy in ctDNA- stage III colon cancer ✅Of XXX patients XXX (72.5%) were ctDNA- ✅Non-inferiority margin: XXX% ✅3-year RFS: XXXX% vs XXXX% XXXX% lower CI = -XXX% (primary endpoint not met) ✅3-year RFS: XXXX% vs XXXX% XXXX% lower CI = -XXX% in clinical low-risk (T1-3N1) subgroup 👉Non-inferiority cannot be demonstrated by ctDNA alone; comprehensive assessment is required including clinical and pathological risk factors. #ESMO25 @OncoReporte @OncoAlert"  
[X Link](https://x.com/DaisukeKotani/status/1980188236484903215) [@DaisukeKotani](/creator/x/DaisukeKotani) 2025-10-20T08:24Z XXX followers, XXX engagements


"🚩2094O: Phase X trial of atezolizumab w/wo tiragolumab for ESCC after definitive CRT (SKYSCRAPER-07) ✅Primary endpoint negative: PFS and OS for atezo + tirago vs. placebo ✅Other primary endpoint OS for atezo vs. placebo: NE vs. XXXX mo HR XXXX p=0.0085 (not formally tested) ✅Secondary endpoint PFS for atezo vs. placebo: XXXX vs. XXXX mo HR XXXX p=0.0113 (not formally tested) 💡Favorable atezo outcomes for ESCC after definitive CRT (similar to PACIFIC strategy) 💡Why did adding tirago reduce efficacy Higher treatment discontinuation due to irAE #ESMO25 @myESMO @Larvol @OncoAlert"  
[X Link](https://x.com/DaisukeKotani/status/1979326706302489011) [@DaisukeKotani](/creator/x/DaisukeKotani) 2025-10-17T23:20Z XXX followers, XXX engagements


"Pleased to share our previous work on consolidation with atezolizumab after definitive CRT for ESCC: a single-arm phase X TENERGY trial @NatureCancer #ESMO25 @myESMO @Larvol @OncoAlert"  
[X Link](https://x.com/DaisukeKotani/status/1979328138082685220) [@DaisukeKotani](/creator/x/DaisukeKotani) 2025-10-17T23:26Z XXX followers, XXX engagements


"🚩LBA81: Final OS from MATTERHORN trial ✅Significant OS improvement with Durvalumab + FLOT vs. placebo + FLOT HR XXXX p=0.021 ✅Consistent efficacy regardless of TAP score 💡D + FLOT is new SOC for localized GC/GEJ adenocarcinoma #ESMO25 @myESMO @Larvol @OncoAlert"  
[X Link](https://x.com/DaisukeKotani/status/1979357327473197295) [@DaisukeKotani](/creator/x/DaisukeKotani) 2025-10-18T01:22Z XXX followers, XXX engagements


"LBA30: STELLAR-303 Zanzalintinib + Atezo vs Rego for pretreated mCRC ✅OS XXXX vs XXX mo HR XXXX p=0.0045 ✅OS benefit at 12-mo: X% ✅PFS XXX vs XXX mo HR XXXX 👉Significant OS improvement with Zanza + Atezo over Rego but absolute median OS gain of XXX mo. Consider balance of efficacy toxicities and QoL. #ESMO25 @myESMO @OncoAlert @OncoReporte"  
[X Link](https://x.com/DaisukeKotani/status/1980186726111785158) [@DaisukeKotani](/creator/x/DaisukeKotani) 2025-10-20T08:18Z XXX followers, 3071 engagements


"751P: Subsequent therapies in BREAKWATER ✅44% of patients discontinuing the control arm treatment received subsequent BRAF inhibitor ✅PFS2 EC + FOLFOX vs Control + 2L EC: XXXX vs XXXX mo 👉Clear PFS2 separation strongly supports 1L EC + FOLFOX for BRAF V600E mutated mCRC #ESMO25 @OncoAlert"  
[X Link](https://x.com/DaisukeKotani/status/1980917793387081856) [@DaisukeKotani](/creator/x/DaisukeKotani) 2025-10-22T08:43Z XXX followers, 2057 engagements